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Abstract 31 
Surgical attenuation of a congenital portosystemic shunts (CPSS) results in 32 
increased portal vein perfusion, liver growth and clinical improvement. Portal 33 
lipopolysaccharide (LPS) is implicated in liver regeneration via toll-like receptor 34 
(TLR) 4 mediated cytokine activation. The aim of this study was to investigate factors 35 
associated with LPS in dogs with CPSS.  36 
Plasma LPS concentrations were measured in the peripheral and portal blood 37 
using a limulus amoebocyte lysate (LAL) assay. LPS concentration was significantly 38 
greater in the portal blood compared to peripheral blood in dogs with CPSS (P = 39 
0.046) and control dogs (P = 0.002). LPS concentrations in the peripheral (P = 0.012) 40 
and portal (P = 0.005) blood of dogs with CPSS were significantly greater than those 41 
for control dogs. The relative mRNA expression of cytokines and TLRs was 42 
measured in liver biopsies from dogs with CPSS using quantitative PCR. TLR4 43 
expression significantly increased following partial CPSS attenuation (P = 0.020). 44 
TLR4 expression was significantly greater in dogs that tolerated complete CPSS 45 
attenuation (P = 0.011) and those with good portal blood flow on pre-attenuation (P = 46 
0.004) and post-attenuation (P = 0.015) portovenography. Serum IL-6 concentration 47 
was measured using a canine specific ELISA and significantly increased 24 h 48 
following CPSS attenuation (P < 0.001).  49 
Portal LPS was increased in dogs with CPSS, consistent with decreased 50 
hepatic clearance. TLR4 mRNA expression was significantly associated with portal 51 
blood flow and increased following surgery. These findings support the concept that 52 
portal LPS delivery is important in the hepatic response to surgical attenuation. Serum 53 
IL-6 significantly increases following surgery, consistent with LPS stimulation via 54 
TLR4, although this increase might be non-specific.  55 
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Introduction 59 
A congenital portosystemic shunt (CPSS) is an abnormal vessel connecting 60 
the portal venous system to the systemic venous system (Payne et al., 1990). A CPSS 61 
allows blood from the splanchnic viscera to bypass the liver, resulting in portal vein 62 
hypoperfusion and hence liver hypoplasia and hepatic insufficiency. Surgical CPSS 63 
attenuation is recommended to restore normal portal blood flow. Successful CPSS 64 
attenuation results in resolution of clinical signs, improvements in hepatic function 65 
and portal perfusion and increased liver volume (Hunt and Hughes, 1999; Kummeling 66 
et al., 2010; Lee et al., 2006; Stieger et al., 2007). These findings suggest that the 67 
return of normal hepatic size and function is achieved by liver regeneration. We have 68 
previously shown that markers of hepatocyte replication are associated with the 69 
degree of liver development and the response to surgery in dogs with CPSS, 70 
supporting a role for hepatic regeneration (Tivers et al., 2014a).  71 
 72 
Hepatic portal blood flow contributes 80% of the afferent liver blood flow and 73 
is vital for normal liver regeneration in people, rodents and dogs (Mathie et al., 1979; 74 
Michalopoulos, 2007). In experimental partial hepatectomy (PH) in pigs and rats, 75 
removal of two thirds of the liver mass caused an effective increase in hepatic portal 76 
blood flow (Kahn et al., 1984; Rice et al., 1977). It is unclear whether liver 77 
regeneration is stimulated by the increase in blood flow or by increased delivery of 78 
hepatotrophic substances in the portal blood (Mortensen and Revhaug, 2011). This 79 
increase in portal blood flow relative to liver mass is similar to that observed 80 
following CPSS attenuation. Intuitively, the response to CPSS attenuation is likely to 81 
be governed by similar factors.  82 
 83 
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Lipopolysaccharide (LPS) or endotoxin is a component of the cell wall of 84 
Gram-negative bacteria and is released following bacterial death. Gram-negative 85 
bacteria are present in the small intestine and therefore LPS is absorbed from the gut 86 
and into the portal vein (Peterson et al., 1991; Howe et al., 1997). LPS has been 87 
shown to play a positive role in liver regeneration in rodent models (Cornell, 1985a, 88 
b, 1990; Gao et al., 1999). Kupffer cells are specialised hepatic macrophages that bind 89 
LPS entering the liver via the portal vein (Freudenberg et al., 1982). LPS acts on 90 
Kupffer cells by binding to toll-like receptor (TLR) 4 (Fenton and Golenbock, 1998). 91 
Kupffer cells produce IL-6 and tumour necrosis factor (TNF) α after stimulation with 92 
LPS in rodents and these cytokines are implicated in the early stages of liver 93 
regeneration (Carswell et al., 1975; Shirahama et al., 1988; Decker et al., 1989; Hori 94 
et al., 1989; Busam et al., 1990). Activation of the cytokine network via LPS 95 
stimulation of Kupffer cells has been suggested as the stimulus for liver regeneration 96 
(Fausto, 2006a). Therefore, it is possible that LPS contributes to triggering the hepatic 97 
response to CPSS attenuation. 98 
 99 
The aim of this study was to investigate whether factors involved in LPS 100 
metabolism are increased after surgical attenuation of canine CPSSs. The first aim 101 
was to measure the concentration of LPS in portal blood compared with peripheral 102 
blood in dogs with CPSS at the time of surgery and control dogs. The second aim was 103 
to measure the hepatic mRNA expression of inflammatory cytokines and TLRs in 104 
dogs with CPSS, before and after partial attenuation. The third aim was to measure 105 
the serum IL-6 concentration before and immediately after CPSS attenuation. The 106 
hypotheses tested were that plasma LPS concentration would be significantly greater 107 
in the portal blood compared with the peripheral blood and that gene expression and 108 
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IL-6 concentration would significantly change in response to surgical CPSS 109 
attenuation.  110 
 111 
Materials and methods 112 
Clinical management 113 
Dogs with CPSS were prospectively recruited between August 2007 and 114 
October 2011. The Ethics Committee of the Royal Veterinary College granted ethical 115 
approval (original approval on 4th June 2004 and updated 22nd October 2010, URN 116 
2010 1058) and owners gave full, informed consent. Dogs were treated surgically via 117 
suture attenuation of their CPSS as previously described (Lee et al., 2006). Dogs that 118 
did not tolerate complete attenuation, due to intra-operative portal hypertension, had 119 
partial suture attenuation. Dogs treated with partial attenuation had repeat surgery 120 
approximately 3 months post-operatively.  121 
 122 
Portovenography was performed before and after temporary complete CPSS 123 
attenuation at each surgery to assess the development of the intrahepatic portal 124 
vasculature as previously described (Lee et al., 2006). Grade was determined 125 
according to the number of generations of intrahepatic portal vessels that were visible 126 
on a scale of 1 - 4 (Lee et al., 2006). Portovenogram grades of 1 and 2 represented 127 
poor portal blood flow and portovenogram grades of 3 and 4 represented good portal 128 
blood flow (Tivers et al., 2014b). 129 
 130 
Healthy experimental Beagle dogs that had been humanely destroyed for 131 
reasons unrelated to hepatic disease were used as controls for all parts of the study. 132 
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Dogs undergoing exploratory laparotomy for reasons unrelated to CPSS were also 133 
included as controls for the measurement of serum IL-6 only.  134 
 135 
Plasma LPS concentration 136 
Paired residual blood samples were taken peri-operatively from the jugular 137 
vein and mesenteric vein of dogs with CPSS. Residual samples were available as a 138 
consequence of placing a jugular central venous catheter pre-operatively and a 139 
mesenteric catheter intra-operatively for the measurement of portal pressures and for 140 
mesenteric portovenography. Blood samples were taken from Beagle control dogs 141 
from the jugular vein immediately before and from the portal vein immediately 142 
following euthanasia.  Samples were collected into heparinised, glass, pyrogen free 143 
tubes (Associates of Cape Cod) and the plasma was separated and stored at -80 °C. 144 
 145 
A limulus amebocyte lysate (LAL) assay using pyrochrome chromogenic 146 
reagent, reconstituted with glucashield beta glucan inhibiting buffer (Associates of 147 
Cape Cod) was used to measure the plasma LPS concentration. Samples were heated 148 
at 75 °C for 10 min and diluted 1:200 with LAL reagent water (Associates of Cape 149 
Cod). Samples were analysed in triplicate using an ELx808 absorbance microplate 150 
reader (BioTek). Sample concentration was calculated from the standard curve using 151 
Gen5 V1.07.5 software (BioTek).   152 
 153 
qPCR Gene Expression 154 
For dogs with CPSS, at each surgery a liver biopsy was taken for routine 155 
diagnostic purposes and a portion was placed in RNAlater (Sigma-Aldrich) and stored 156 
according to manufacturer’s instructions. Liver tissue was taken from Beagle control 157 
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dogs immediately following euthanasia and stored in the same way. Routine 158 
histopathology was performed on sections stained with haematoxylin and eosin.  159 
 160 
RNA was extracted from approximately 20-30 mg of each hepatic sample 161 
using the GenElute Mammalian Total RNA Miniprep Kit (Sigma-Aldrich). The tissue 162 
was homogenised in 500 µL Lysis Solution using a Mixer Mill MM 300 (Retsch). An 163 
in-solution DNase digestion was performed using the Ambion TURBO DNA-free Kit 164 
(Life Technologies) to remove any contaminating DNA. RNA quality and quantity 165 
was assessed by microfluidic capillary electrophoresis using the Agilent 2100 166 
Bioanalyser (Agilent Technologies). The median RNA integrity number was 8.3 167 
(range, 7.1-9.2). No samples had genomic DNA contamination. Two separate cDNA 168 
were synthesised from each RNA sample using a mixture of random hexamer and 169 
oligo (dT)15 primers (Promega) and IMProm-II reverse transcriptase enzyme 170 
(Promega). Where possible, the amount of RNA template for cDNA synthesis was 171 
standardised at 1 µg. The cDNA was diluted to a final volume of 100 µL with 172 
nuclease-free water and stored at -20 °C before further use. 173 
 174 
Relative hepatic expression of five genes related to hepatic LPS signalling (IL-175 
1β, IL-6, TNFα, TLR2 and TLR4) was measured using quantitative polymerase chain 176 
reaction (qPCR). Published canine specific primers for the genes of interest (Wang et 177 
al., 2007; House et al., 2008) and four liver specific reference genes, hydroxymethyl-178 
bilane synthase, ribosomal protein L13a, ribosomal protein L32 and ribosomal protein 179 
S18, were used (Peters et al., 2007; Table 1). 180 
  181 
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For quantification, each liver sample had two cDNA samples analysed in 182 
duplicate. Reactions were carried out in 25 µL volumes using a Bio-Rad CFX96 Real-183 
Time PCR Detection System thermocycler (Bio-Rad Laboratories). Each reaction 184 
consisted of 1 L cDNA as the template with Immobuffer (1 × concentration), Hi-185 
Spec Additive (1 × concentration), dNTP (final concentration 1 mM), magnesium 186 
chloride (final concentration 2.5mM for genes of interest, 4.5mM for reference 187 
genes), 1 unit Immolase DNA polymerase (Bioline) and EvaGreen dye (Biotium; 0.06 188 
× diluted 1:4 with nuclease-free water). Samples were incubated at 95 °C for 10 min 189 
followed by 40 cycles of denaturation at 94 °C for 30 s, annealing at 55 °C for 30 s 190 
and elongation at 72 °C for 10 s. An appropriate primer-dimer melting temperature 191 
for 1 s was programmed before fluorescence readings were taken at the end of each 192 
cycle. A melting curve analysis from 65 oC to 95 oC with a plate read every 0.5 oC 193 
was performed at the end of 40 cycles. Bio-Rad CFX Manager Software (Bio-Rad) 194 
was used for initial qPCR analysis.  195 
 196 
Analysis of raw real-time data was performed using GenEx professional 197 
version 4.4.2 software (Multid Analyses). Relative gene expression was quantified as 198 
previously described (Vandesompele et al., 2002). Quantification cycle (Cq) values 199 
were corrected using the calculated efficiencies for each primer set. Normalisation of 200 
each sample Cq for the genes of interest was performed relative to the geometric 201 
normalisation of the four reference genes. The relative expression of the mRNA of 202 
each gene of interest in each cDNA sample was then calculated using the normalised 203 
Cq of each sample relative to the average Cq of all of the samples. For each gene the 204 
following comparisons were made: CPSS compared to control; partial attenuation 205 
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compared to complete attenuation; before and after partial attenuation (paired 206 
samples). 207 
 208 
Serum IL-6 concentration 209 
Blood samples were taken from both dogs with CPSS and control dogs that 210 
underwent exploratory laparotomy pre-operatively for diagnostic purposes and after 211 
surgery in dogs with CPSS for post-operative monitoring.  Where available, residual 212 
blood was used for the study. Residual blood samples were also taken immediately 213 
before euthanasia in Beagle control dogs. The serum was separated and stored at -80 214 
°C. 215 
 216 
A Quantikine Canine ELISA Kit (R and D Systems) was used to measure the 217 
serum concentration of IL-6 (Song et al., 2012). Samples were analysed in duplicate 218 
using an ELx808 absorbance microplate reader (BioTek). Sample concentration was 219 
calculated from the standard curve using Gen5 V1.07.5 software (BioTek). 220 
 221 
Statistical analysis 222 
Analysis was performed using PASW Statistics 18.0.0 statistical software 223 
package (Education SPSS, IBM). Continuous data were visually assessed for 224 
normality.  Median and range were reported for skewed data, which was compared 225 
with the Mann Whitney U test or the Wilcoxon signed-ranks test as appropriate. 226 
Repeated measures were compared with the Friedman’s two-way analysis of variance 227 
by ranks with pair-wise comparison. The LPS concentration and qPCR data was 228 
transformed to normal distribution (square root or logarithm). The data was then 229 
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compared with an independent t test or paired sample t test. Significance was set at 230 
the 5% level (P ≤ 0.05).  231 
 232 
Results 233 
Plasma LPS concentration 234 
Paired peripheral and portal plasma samples from 13 dogs with CPSS were 235 
included. The following breeds were included: Bichon Frise (n=2), Labrador (n=2), 236 
Border terrier (n=1), Cavalier King Charles spaniel (n=1), Crossbreed (n=1), Dogue 237 
de Bordeaux (n=1), German shepherd dog (n=1), Miniature Schnauzer (n=1), 238 
Springer spaniel (n=1), West Highland white terrier (n=1), Yorkshire terrier (n=1). 239 
The median age was 295 days (range, 125-1835 days). Nine dogs (69.2%) had an 240 
extrahepatic CPSS and four (30.8%) had an intrahepatic CPSS.  241 
 242 
Paired peripheral and portal plasma samples from nine healthy Beagles were 243 
included as control dogs. The median age was 1136 days (range, 497-1660 days), 244 
which was significantly greater than dogs with CPSS (P = 0.036). 245 
 246 
For dogs with CPSS, the median LPS concentration in the portal blood was 247 
0.453 endotoxin units (EU)/mL (range, 0.117-1.418 EU/mL), which was significantly 248 
greater than that in the peripheral blood (0.239 EU/mL; range, 0.056-1.410 EU/mL; P 249 
= 0.046; Fig. 1). For Beagle control dogs, the median LPS concentration in the portal 250 
blood was 0.184 EU/mL (range, 0.126-0.565 EU/mL), which was significantly greater 251 
than that in the peripheral blood (0.131 EU/mL; range, 0.061-0.187 EU/mL; P = 252 
0.002; Fig. 1). The LPS concentrations in the peripheral blood (P = 0.012) and portal 253 
12 
 
blood (P = 0.005) of dogs with CPSS were both significantly greater than for Beagle 254 
control dogs (Fig. 1).  255 
 256 
 257 
qPCR gene expression 258 
Liver samples obtained at the first surgery were available from 49 dogs. The 259 
following breeds were included: Yorkshire terrier (n=7), Crossbreed (n=6), Labrador 260 
(n=5), Miniature Schnauzer (n=5), West Highland white terrier (n=5), Cocker spaniel 261 
(n=4), Jack Russell terrier (n=3), Bichon Frise (n=2), Golden retriever (n=2), Lhasa 262 
Apso (n=2), Pug (n=2), Chihuahua (n=1), Hovawart (n=1), Irish Setter (n=1), Norfolk 263 
terrier (n=1), Old English sheepdog (n=1), Staffordshire bull terrier (n=1). The 264 
median age was 275 days (range, 97-4374 days). Thirty-eight (77.6%) dogs had an 265 
extrahepatic CPSS and 11 (22.4%) had an intrahepatic CPSS. Of the 49 dogs that had 266 
surgery, 24 (49%) had complete attenuation and 25 (51%) had partial attenuation. The 267 
25 dogs that had partial attenuation had repeat surgery a median of 110 days post-268 
operatively (range, 69-358 days). At the time of this repeat surgery, liver samples 269 
from these 25 dogs were obtained for a second analysis, enabling comparison of 270 
results with those from the first liver samples. At second surgery, 20 dogs tolerated 271 
complete CPSS attenuation, three dogs had progressed to complete shunt occlusion 272 
spontaneously (no flow on portovenography), and two dogs had developed multiple 273 
acquired shunts. The liver of all dogs with CPSS at first and second surgery showed 274 
characteristic changes consistent with portal hypoperfusion. No additional pathology 275 
was noted. Liver samples were acquired from seven Beagle control dogs as controls. 276 
The median age of control dogs was 628 days (range, 515-1544 days), which was 277 
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significantly older than for dogs with CPSS (P = 0.036). The liver of all control dogs 278 
was histopathologically unremarkable. The results are summarised in Table 2. 279 
 280 
Relative mRNA expression of IL-1β (P = 0.016) and IL-6 (P = 0.002) were 281 
both significantly greater for dogs with CPSS than for Beagle control dogs (Fig. 2). 282 
Relative TLR4 mRNA expression was significantly greater in dogs with complete 283 
attenuation compared with those with partial attenuation (P = 0.011; Fig. 2). Relative 284 
TLR4 mRNA expression significantly increased following partial attenuation (P = 285 
0.020; Fig. 2). Relative TLR4 mRNA expression was also compared between dogs 286 
with poor portal blood flow and those with good portal blood flow on 287 
portovenography (further details below). Relative TLR4 mRNA expression was 288 
significantly greater in dogs with good portal blood flow compared to those with poor 289 
portal blood flow on both pre-attenuation (P = 0.004) and post-attenuation 290 
portovenograms (P = 0.015; Fig. 3, Table 3).  291 
 292 
No significant associations were demonstrated for the relative mRNA 293 
expression of TNFα or TLR2.  294 
 295 
Portovenogram grading 296 
Complete portovenograms were available for 47/49 dogs at first surgery and 297 
21/25 dogs at second surgery. Pre-attenuation and post-attenuation portovenogram 298 
grades at first surgery were significantly greater for dogs with complete attenuation 299 
compared with dogs with partial attenuation (P < 0.001 for each). For dogs treated 300 
with partial attenuation, there was a significant increase in both pre-temporary CPSS 301 
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attenuation portovenogram grade (P < 0.001) and post-temporary CPSS attenuation 302 
portovenogram grade  (P = 0.001) from first to second surgery (Table 4).  303 
 304 
Serum IL-6 concentration 305 
Serum samples taken before and at 24 and 48 h post-surgery from 22 dogs 306 
with CPSS were analysed. The following breeds were included: Yorkshire terrier 307 
(n=4), Norfolk terrier (n=3), West Highland white terrier (n=3), Jack Russell terrier 308 
(n=2), Miniature Schnauzer (n=2), Shih Tzu (n=2), British bulldog (n=1), Crossbreed 309 
(n=1), Golden retriever (n=1), Labrador (n=1), Miniature Dachshund (n=1), Shetland 310 
sheepdog (n=1). The median age was 334.5 days (range, 114-2282 days). Nineteen 311 
(86.4%) dogs had an extrahepatic CPSS and three (13.6%) had an intrahepatic CPSS. 312 
Twelve dogs (54.5%) had complete attenuation and 10 (45.5%) had partial 313 
attenuation.  314 
 315 
Serum samples from seven healthy Beagles and five dogs undergoing 316 
abdominal surgery were included as controls. The following breeds were included in 317 
the abdominal surgery controls: Crossbreed (n=2), Golden retriever (n=1), Labrador 318 
(n=1), Shar Pei (n=1). The dogs were undergoing abdominal surgery for the 319 
investigation or treatment of insulinoma, adrenal carcinoma, splenic carcinoma, 320 
phaeochromocytoma and extrahepatic biliary tract obstruction. The median age of 321 
control dogs was 925 days (range, 526-4204 days); they were significantly older than 322 
dogs with CPSS (P < 0.001).  323 
 324 
There was no significant difference in pre-operative IL-6 concentrations 325 
between dogs with CPSS (median, 0 pg/mL; range, 0-876.75 pg/mL) and control dogs 326 
15 
 
(median, 0 pg/mL; range, 0-40.66 pg/mL). The median IL-6 concentration at 24 h in 327 
dogs with CPSS was 34.461 pg/mL (range, 0-483.726 pg/mL) and at 48 h was 8.137 328 
pg/mL (range, 0-683.925 pg/mL; Fig. 4). In dogs with CPSS, there was a significant 329 
difference in the concentration of IL-6 at the different time points (P < 0.001). Pair-330 
wise comparison of this data set confirmed that IL-6 at 24 h post-surgery was 331 
significantly greater than pre-surgery (P < 0.001). 332 
 333 
Discussion 334 
We measured the LPS concentration in peripheral and portal blood samples 335 
from dogs with CPSS and healthy Beagle control dogs. In normal animals and 336 
humans, LPS from the gut is transported to the liver by the portal system and is 337 
cleared by the Kupffer cells (Bradfield, 1974; Zlydaszyk and Moon, 1976; Jacob et 338 
al., 1977). Therefore, LPS is routinely detected in the portal circulation, but only a 339 
small amount is found in peripheral venous blood (Prytz et al., 1976; Jacob et al., 340 
1977). Portal LPS concentrations are significantly greater than peripheral 341 
concentrations in both healthy humans and those with liver disease (Tachiyama et al., 342 
1988; Lumsden et al., 1988; Benten et al., 2011; Sanada et al., 2012). However, LPS 343 
is increased in both the peripheral and portal blood of humans with liver cirrhosis due 344 
to increased absorption from the gut and decreased hepatic clearance (Lumsden et al., 345 
1988; Tachiyama et al., 1988; Lin et al., 1995; Kaser et al., 2002). This increase is 346 
thought to be due to either the shunting of blood past the liver via multiple acquired 347 
shunts (MAS) or impaired LPS clearance due to liver pathology (Kaser et al., 2002).  348 
 349 
Our study demonstrated that portal LPS concentration was significantly 350 
greater than peripheral concentration in dogs with CPSS and Beagle control dogs. 351 
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Peripheral and portal LPS concentrations were also significantly greater in dogs with 352 
CPSS compared to Beagle control dogs. These findings are consistent with those in 353 
humans. It is unsurprising that LPS concentrations were significantly greater in dogs 354 
with CPSS, as hepatic clearance is reduced as a consequence of shunting, as in 355 
humans with MAS. However, in people with liver cirrhosis there is also increased 356 
absorption of LPS from the gut, which is presumably not the case in dogs with CPSS. 357 
Thus, the main reason for the increase in LPS is likely to be decreased hepatic 358 
clearance. A previous study measured LPS in the peripheral and portal blood of 10 359 
dogs with CPSS compared with five control dogs using an LAL assay (Peterson et al., 360 
1991). Contrary to our study, there were no significant differences in LPS 361 
concentrations between peripheral and portal samples or between CPSS and control 362 
dogs. The reason for this discrepancy could be due to differences in experimental 363 
methodology or to variables in the dogs studied. Another study measured LPS 364 
concentration in the portal vein, hepatic vein and caudal vena cava of 10 dogs with 365 
experimentally created MAS and six control dogs using an LAL assay (Howe et al., 366 
1997). In agreement with our study, LPS concentration was significantly greater in all 367 
vessels for dogs with MAS compared with control dogs.  368 
 369 
In our study, and in the two canine studies mentioned above, an LAL assay 370 
was used to measure plasma LPS concentration. The LAL assay has been commonly 371 
used to measure plasma LPS in people with liver disease (Jacob et al., 1977; Lumsden 372 
et al., 1988; Tachiyama et al., 1988; Lin et al., 1995; Benten et al., 2011). Many 373 
variables can affect assay results and there is considerable variation in methodology 374 
between studies, which can affect the sensitivity and reliability of the LAL assay 375 
(Novitsky, 1994; Hurley, 1995). The endotoxin activity assay (EAA) is a more recent 376 
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technique for measuring endotoxin and uses chemiluminescence of neutrophil activity 377 
(Romaschin et al., 1998; Marshall et al., 2002). It has been used in both humans and 378 
dogs and is considered to be more accurate than the LAL method (Marshall et al., 379 
2002; Kjelgaard-Hansen et al., 2008; Sanada et al., 2011). It is possible that inclusion 380 
of the EAA test in our methodology might have improved the reliability of our results, 381 
but this test was not available to us for logistical and financial reasons. 382 
 383 
Our findings demonstrated that LPS concentration was increased in the portal 384 
blood of dogs with CPSS, most likely due to decreased hepatic clearance, suggesting 385 
that reduced delivery of portal blood to the liver is accompanied by reduced LPS 386 
delivery to the liver. This is consistent with the concept that portal delivery of LPS to 387 
the liver is a potential trigger for the hepatic response to attenuation. Surgical CPSS 388 
attenuation increases portal blood flow and hence increases LPS delivery to the liver. 389 
Following CPSS attenuation, normalisation of LPS concentrations is expected due to 390 
increased hepatic clearance. However, follow-up samples were not available so this 391 
was not assessed.  392 
 393 
We have demonstrated that there was a significant increase in serum IL-6 at 394 
24 h following CPSS attenuation. IL-6 is a key mediator of the initial stages of 395 
hepatic regeneration and rapid increases in hepatic and serum IL-6 are observed 396 
following PH in rodents (Cressman et al., 1996; Sakamoto et al., 1999; Iwai et al., 397 
2001; Aldeguer et al., 2002). Increased portal blood flow results in stimulation of 398 
Kupffer cells and release of IL-6, an initiator of regeneration (Decker, 1990; Meijer et 399 
al., 2000; Abshagen et al., 2007; Riehle et al., 2008).  The increase in IL-6 in dogs 400 
with CPSS following attenuation could, at least in part, be due to increased hepatic 401 
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blood flow and IL-6 release as part of liver regeneration. However, there is another 402 
possible explanation for the increase in IL-6. Abdominal surgery in humans is 403 
associated with an inflammatory response, resulting in increased IL-6 in the 404 
peripheral and portal blood (Cruickshank et al., 1990; Di Padova et al., 1991; Baigrie 405 
et al., 1992; Glaser et al., 1995; Biffl et al., 1996; Kimura et al., 1998). Logically, the 406 
increase in serum IL-6 following CPSS surgery might also be due to surgical trauma. 407 
A control group of dogs undergoing laparotomy for reasons unrelated to CPSS 408 
attenuation with pre- and post-operative serum samples would have provided more 409 
information on the specificity of post-operative increase in IL-6.  410 
 411 
Significant post-operative increases in serum IL-6 are seen in humans 412 
undergoing PH for tumour resection and in individuals donating or receiving liver 413 
transplants (Kimura et al., 1998, 1999; Hu et al., 1999; Asakura et al., 2000; Chijiiwa 414 
et al., 2002; Slotwinski et al., 2002). One study demonstrated a significant increase in 415 
serum IL-6 at 24, 72 and 168 h post-hepatectomy for liver donation, but there was no 416 
significant increase post-hepatectomy for benign neoplasia (Slotwinski et al., 2002). 417 
The study concluded that in humans with normal livers, IL-6 increased following 418 
partial hepatectomy, consistent with hepatic regeneration. This is similar to the 419 
findings of our study, although IL-6 rapidly returned to normal, whereas it remained 420 
increased in people following hepatectomy. In other studies of abdominal surgery in 421 
people, IL-6 levels increase rapidly to peak at 4-48 h post-operatively, but can remain 422 
increased for 48-72 h (Di Padova et al., 1991; Baigrie et al., 1992; Biffl et al., 1996). 423 
The reason for these discrepancies is unclear, but could be related to differences in the 424 
nature of the surgery and therefore the hepatic response, species differences, 425 
differences in methodology and assay sensitivity. However, pre-existing liver disease 426 
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is associated with increased IL-6 and this could affect post-operative changes (Hu et 427 
al., 1999; Slotwinski et al., 2002). Similarly, dogs with liver disease have increased 428 
serum IL-6 concentrations compared with healthy dogs (Neumann et al., 2012). In a 429 
recent study, plasma IL-6 concentrations were increased in dogs with CPSS 430 
(Kilpatrick et al., 2014). Our study did not find a significant difference in serum IL-6 431 
concentrations between CPSS and control dogs. However, it is possible that 432 
differences in the populations and methodology could be responsible for this 433 
discrepancy. Additionally, our study had a relatively small number of control dogs, 434 
perhaps resulting in a type II statistical error.  435 
 436 
We measured the expression of IL-1β, IL-6 and TNFα mRNA in liver tissue. 437 
The expression of both IL-1β and IL-6 mRNA in liver tissue were significantly 438 
greater in dogs with CPSS compared to Beagle control dogs. IL-1β, IL-6 and TNFα 439 
are inflammatory cytokines that are released by Kupffer cells in response to 440 
stimulation by LPS (Shirahama et al., 1988; Decker et al., 1989; Busam et al., 1990). 441 
IL-6 and TNFα are initiators of regeneration and IL-1β inhibits regeneration (Boulton 442 
et al., 1997; Fausto et al., 2006b; Riehle et al., 2011). Therefore, it seems incongruous 443 
that both IL-6 and TNFα are increased in an underdeveloped CPSS liver. As 444 
mentioned above, abdominal surgery initiates an inflammatory response accompanied 445 
by increases in serum IL-6 and IL-1β; increases in IL-1β precede those for IL-6 446 
(Baigrie et al., 1992; Glaser et al., 1995; Kimura et al., 1998). It is possible that liver 447 
biopsy would result in similar increases in IL-1β and IL-6 in the traumatised tissue. 448 
Therefore, the increased cytokine expression in CPSS liver tissue could be due to 449 
acute release following surgical trauma. As control liver tissue was obtained post-450 
mortem, there might not have been similar increases in cytokine expression. 451 
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However, this potential explanation is conjecture and remains unproven. Several 452 
studies have shown that dogs with CPSS, and in particular those with hepatic 453 
encephalopathy, have evidence of generalised inflammation with increased serum IL-454 
6, plasma C-reactive protein (CRP) and systemic inflammatory response syndrome 455 
scores (Gow et al., 2012; Kilpatrick et al., 2014; Tivers et al., 2014c, 2015). It is 456 
possible that more generalised increases in IL-1β and IL-6 as a result of pre-existing 457 
inflammation could be responsible for the increased hepatic expression of these 458 
cytokines. It is also possible that differences in IL-1β and IL-6 between the CPSS and 459 
control dogs could have been due to differences in breed and age between the two 460 
groups. However, if this were the case, a physiological reason for this difference is 461 
unclear.  462 
 463 
We measured the hepatic mRNA expression of TLR2 and TLR4. TLR4 464 
mRNA expression was significantly increased in dogs with CPSS tolerating complete 465 
attenuation compared to those which tolerated only partial attenuation. Dogs with 466 
well-developed intrahepatic portal vasculature on portovenography had significantly 467 
increased TLR4 mRNA expression. Additionally, TLR4 mRNA expression 468 
significantly increased following partial attenuation.  In contrast, no significant 469 
differences were identified for TLR2.  This finding might be because TLR2 plays a 470 
major role in detection of Gram-positive bacteria, recognising components of the cell 471 
wall including peptidoglycan, lipoteichoic acid and lipoproteins (Yoshimura et al., 472 
1999).   Gram-positive bacteria are not the predominant component of typical gut 473 
flora. The absence of a significant difference in TLR2 mRNA expression in 474 
conjunction with a significant increase in TLR4 mRNA expression increases the 475 
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likelihood that these data reflect a specific interaction between gut flora pathogen-476 
associated molecular patterns and the hepatic response to CPSS attenuation. 477 
 478 
TLR4 is expressed by Kupffer cells and binds LPS, enabling circulatory 479 
clearance of LPS (Freudenberg et al., 1982; Fenton and Golenbock, 1998). LPS is 480 
very important for normal hepatic regeneration (Cornell, 1985a, b, 1990; Gao et al., 481 
1999). Kupffer cell release of IL-6 and TNFα in response to LPS is implicated in the 482 
initiation of hepatic regeneration (Fausto, 2006a). Increased expression of TLR4 483 
mRNA suggests increased LPS binding capacity in dogs with CPSS and good portal 484 
blood flow and in those able to tolerate complete attenuation. As partial attenuation 485 
increases portal blood flow, increased TLR4 mRNA is therefore consistent with 486 
increased LPS delivery. This provides further evidence that TLR4 and blood flow are 487 
important in the hepatic response to surgery.  These findings demonstrate that TLR4 488 
mRNA expression is linked with portal blood flow and in the response to surgical 489 
attenuation in dogs with CPSS. We have previously shown that the hepatic expression 490 
of hepatocyte growth factor (HGF) and methionine adenosyltransferase 2 A, which 491 
are both markers of hepatocyte replication, are significantly increased following 492 
partial CPSS attenuation (Tivers et al., 2014a). We have also shown that vascular 493 
endothelial growth factor receptor 2 (VEGFR2) is significantly associated with the 494 
degree of portal blood flow and significantly increases following partial CPSS 495 
attenuation (Tivers et al., 2014b). In addition, these studies also demonstrated that 496 
there were significant increases in HGF and VEGF immediately following CPSS 497 
surgery (Tivers et al., 2014a, b). These data suggest that both hepatic regeneration, in 498 
the form of hepatocyte replication and angiogenesis, are associated with CPSS 499 
attenuation. The findings of the current study are in broad agreement with these 500 
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findings and support the concept that activation of Kupffer cells via TLR4 binding of 501 
LPS could be involved in this process. Further work is needed to explore this concept. 502 
 503 
There are a number of limitations to the current study that must be taken into 504 
account. The number of dogs included in the study was relatively small, particularly 505 
for the measurement of plasma LPS and in the control groups for the other 506 
experiments. Larger group size might have allowed further statistically significant 507 
findings to be identified. Nevertheless, we were able to identify a number of findings 508 
that were both biologically relevant and statistically significant. In addition, the 509 
experimental Beagles used as control dogs were significantly older than the dogs with 510 
CPSS. Consequently, it is possible that the differences detected in LPS concentration 511 
and cytokine mRNA expression could have been related to breed or age rather than to 512 
CPSS.   513 
 514 
Conclusions 515 
Our results have demonstrated that portal LPS is increased in dogs with CPSS, 516 
consistent with decreased hepatic clearance due to shunting. In addition, hepatic 517 
TLR4 mRNA expression was significantly associated with portal blood flow and 518 
significantly increased following CPSS attenuation. This suggests that LPS binding 519 
capacity via TLR4 is linked to blood flow and the degree of portal development. This 520 
provides supporting evidence for the concept that LPS triggers liver regeneration via 521 
Kupffer cell binding and signalling following CPSS attenuation. Further 522 
investigations are warranted to explore this mechanism in more depth. 523 
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Table 1 856 
Table showing details of reference gene and gene of interest primer pairs for quantitative PCR. 857 
 858 
Gene Primer sequences PCR amplicon 
length (bp) 
Genbank accession 
number 
Primer sequence 
reference 
HMBS Forward: TCACCATCGGAGCCATCT 
Reverse: GTTCCCACCACGCTCTTCT 
112 XM546491 Peters et al., 2007 
RPL13A Forward: GCCGGAAGGTTGTAGTCGT 
Reverse: GGAGGAAGGCCAGGTAATTC 
87 AJ388525 Peters et al., 2007 
RPL32 Forward: TGGTTACAGGAGCAACAAGAAA 
Reverse: GCACATCAGCAGCACTTCA 
100 XM_848016 Peters et al., 2007 
RPS18 Forward: TGCTCATGTGGTATTGAGGAA 
Reverse: TCTTATACTGGCGTGGATTCTG 
116 XM_532106 Peters et al., 2007 
IL-1β Forward: TCTCCCACCAGCTCTGTAACAA 
Reverse: GCAGGGCTTCTTCAGCTTCTC 
80 Z70047 Wang et al., 2007 
IL-6 Forward: TCCTGGTGATGGCTACTGCTT 
Reverse: GACTATTTGAAGTGGCATCATCCTT 
78 U12234 Wang et al., 2007 
TNFα Forward: GAGCCGACGTGCCAATG 
Reverse: CAACCCATCTGACGGCACTA 
79 Z70046 Wang et al., 2007 
TLR2 Forward: AGTGGCCAGAAAAGCTGAAA  
Reverse: ATCCAGTTGCTCCTTCGAGA 
263 NM001005264 House et al., 2008 
TLR4 Forward: CAAAATCCCCAACAACATCC 
Reverse: TGGTTTAGGCCCTGATATGC 
171 NM001002950 House et al., 2008 
bp, base pairs; HMBS, hydroxymethyl-bilane synthase; RP, ribosomal protein; TNF, tumour necrosis factor; TLR, toll-like receptor   859 
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Table 2 860 
Relative mRNA expression of cytokines and toll-like receptors (normalised with respect to four liver specific reference genes) in liver biopsies 861 
from 49 dogs with congenital portosystemic shunts (CPSS) and seven Beagle control dogs. Results are presented as median and range.  862 
Gene Control compared to CPSS Complete attenuation compared to partial 
attenuation 
Before and after partial attenuation 
(n=25) 
Control a 
(n=7) 
CPSS 
(n=49) 
P  Partial 
(n=25) 
Complete 
(n=24) 
P  Before partial 
attenuation 
After partial 
attenuation 
P  
IL-1β 3.351 
(2.361-5.723) 
11.172 
(1.654-919.494) 
0.016b 7.817 
(1.654-197.141) 
11.849 
(2.826-919.494) 
0.052 7.817 
(1.654-197.141) 
8.981 
(1.975-169.281) 
0.800 
IL-6 2.569 
(1.288-3.463) 
9.473 
(1.581-332.589) 
0.002b 8.310 
(1.914-332.589) 
13.044 
(1.581-229.601) 
0.421 8.310 
(1.914-332.589) 
5.543 
(1.548-207.752) 
0.155 
TNFα 2.554 
(2.158-4.402) 
2.818 
(1.509-11.364) 
0.772 2.736 
(1.509-5.917) 
2.833 
(1.544-11.364) 
0.601 2.736 
(1.509-5.917) 
2.748 
(1.326-14.032) 
0.174 
TLR2 2.041 
(1.700-3.525) 
2.241 
(1.396-9.904) 
0.298 2.204 
(1.396-5.046) 
2.242 
(1.602-9.904) 
0.401 2.204 
(1.396-5.046) 
2.372 
(1.189-12.289) 
0.148 
TLR4 4.340 
(4.005-7.049) 
5.067 
(1.581-20.575) 
0.396 4.337 
(1.581-14.505) 
6.189 
(3.183-20.575) 
0.011b 4.337 
(1.581-14.505) 
6.065 
(1.627-11.617) 
0.020b 
IL, interleukin; TNF, tumour necrosis factor; TLR, toll-like receptor 863 
a Beagle dogs 864 
b Statistically significant value (P ≤ 0.05) 865 
  866 
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Table 3 867 
Relative mRNA expression of toll-like receptor 4 (TLR4), normalised with respect to four liver specific reference genes, in liver biopsies from 868 
47 dogs with congenital portosystemic shunts as related to portal blood flow on pre-attenuation and post-attenuation portovenogram, at first 869 
surgery. Results are presented as median and range.  870 
Gene Pre-attenuation portal blood flow Post-attenuation portal blood flow 
Poor 
(35 dogs) 
Good 
(12 dogs) 
P  Poor 
(12 dogs) 
Good 
(35 dogs) 
P  
TLR4 4.607 
(1.581-14.505) 
7.638 
(3.423-20.575) 
0.004a 4.271 
(1.581-8.060) 
5.513 
(2.188-20.575) 
0.01 a 
a Statistically significant value (P ≤ 0.05) 871 
 872 
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Table 4 873 
Portovenogram grade before and after temporary congenital portosystemic shunt 874 
attenuation in 21 dogs at first and second surgery. This group of dogs all had a partial 875 
attenuation at the first surgery. There was a significant increase in portovenogram 876 
grade for both pre-attenuation and post-attenuation from first to second surgery (P < 877 
0.001 and P = 0.001, respectively).  878 
 879 
Timing of assessment n (%) dogs for each portovenogram grade 
Grade 1 Grade 2 Grade 3 Grade 4 
1st Surgery Pre-attenuation 18 (85.7) 3 (14.3) 0 (0) 0 (0) 
1st Surgery Post-attenuation 0 (0) 12 (57.1) 9 (42.9) 0 (0) 
2nd Surgery Pre-attenuation 2 (9.5) 8 (38.1) 6 (28.6) 5 (23.8) 
2nd Surgery Post-attenuation 0 (0) 4 (19.0) 6 (28.6) 10 (52.4) 
  880 
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Figure legends 881 
Fig. 1. Measurement of lipopolysaccharide (LPS) concentration (endotoxin units 882 
[EU]/mL) in peripheral and portal plasma from 13 dogs with congenital portosystemic 883 
shunts (CPSS) and nine healthy Beagle control dogs using a limulus amebocyte lysate 884 
(LAL) assay. Statistical significance is highlighted with the corresponding P value. 885 
(A) Peripheral and portal LPS concentration in dogs with CPSS. (B) Peripheral and 886 
portal LPS concentrations in Beagle control dogs. (C) Peripheral LPS concentration in 887 
Beagle control dogs compared with dogs with CPSS. (D) Portal LPS concentration in 888 
Beagle control dogs compared with dogs with CPSS.  889 
 890 
 891 
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Fig. 2. Relative cytokine and toll-like receptor mRNA expression (normalised with 892 
respect to four liver specific reference genes) in liver biopsies from 49 dogs with 893 
congenital portosystemic shunts (CPSS) and seven Beagle control dogs. The graphs 894 
show statistically significant findings for the five genes assessed. Statistical 895 
significance is highlighted with the corresponding P value. (A) Interleukin 1 beta (IL-896 
1β) mRNA expression in Beagle control dogs compared with dogs with CPSS. (B) 897 
Interleukin 6 (IL-6) mRNA expression in Beagle control dogs compared with dogs 898 
with CPSS. (C) Toll-like receptor 4 (TLR4) mRNA expression in dogs with CPSS 899 
tolerating a partial attenuation compared with those tolerating a complete attenuation. 900 
(D) TLR4 mRNA expression in dogs with CPSS at first surgery compared with 901 
second surgery. 902 
 903 
 904 
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Fig. 3. Relative mRNA expression of toll-like receptor 4 (TLR4), normalised with 905 
respect to four liver specific reference genes, in liver biopsies from 47 dogs with 906 
congenital portosystemic shunts (CPSS) as related to portal blood flow on pre-907 
attenuation and post-attenuation portovenogram. Portovenogram grades of 1 and 2 908 
were considered poor portal blood flow and portovenogram grades of 3 and 4 were 909 
considered good portal blood flow. Statistical significance is highlighted with the 910 
corresponding P value. (A) TLR4 mRNA expression in dogs with CPSS with poor 911 
portal blood flow compared with dogs with CPSS with good portal blood flow on pre-912 
attenuation portovenogram. (B) TLR4 mRNA expression in dogs with CPSS with 913 
poor portal blood flow compared with dogs with CPSS with good portal blood flow 914 
on post-attenuation portovenogram.  915 
 916 
  917 
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Fig. 4. Serum interlukin 6 (IL-6) concentration in 22 dogs with congenital 918 
portosystemic shunts pre-surgery and at 24 and 48 h post-surgery. IL-6 concentration 919 
was measured using a canine IL-6 ELISA kit. There was a significant difference in 920 
the concentration of IL-6 at the different time points (P < 0.001). Pair-wise 921 
comparison of this data set confirmed that IL-6 at 24 h post-surgery was significantly 922 
greater than pre-surgery (P < 0.001). 923 
 924 
